M&G PLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 76.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,860 shares of the company’s stock after selling 5,932 shares during the period. M&G PLC’s holdings in Eli Lilly and Company were worth $2,152,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in the stock. Integrity Financial Corp WA boosted its stake in shares of Eli Lilly and Company by 1.3% during the second quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock valued at $767,000 after acquiring an additional 8 shares during the last quarter. LCM Capital Management Inc raised its stake in Eli Lilly and Company by 3.3% in the 3rd quarter. LCM Capital Management Inc now owns 253 shares of the company’s stock valued at $293,000 after purchasing an additional 8 shares during the last quarter. Smith Shellnut Wilson LLC ADV raised its stake in Eli Lilly and Company by 4.1% in the 3rd quarter. Smith Shellnut Wilson LLC ADV now owns 203 shares of the company’s stock valued at $235,000 after purchasing an additional 8 shares during the last quarter. Financial Network Wealth Advisors LLC raised its stake in Eli Lilly and Company by 5.6% in the 3rd quarter. Financial Network Wealth Advisors LLC now owns 151 shares of the company’s stock valued at $175,000 after purchasing an additional 8 shares during the last quarter. Finally, Eads & Heald Wealth Management lifted its holdings in Eli Lilly and Company by 0.5% in the 3rd quarter. Eads & Heald Wealth Management now owns 1,469 shares of the company’s stock valued at $1,700,000 after purchasing an additional 8 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on LLY shares. Leerink Partners raised their price target on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 21st. Sanford C. Bernstein reiterated an “outperform” rating and set a $1,450.00 price target on shares of Eli Lilly and Company in a report on Monday, October 26th. Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Argus upped their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Finally, Bank of America reissued a “buy” rating and set a $1,497.00 price objective on shares of Eli Lilly and Company in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,416.64.
View Our Latest Research Report on LLY
Key Headlines Impacting Eli Lilly and Company
These are some of the LLY headlines that stood out recently:
- Positive Sentiment: Foundayo, Lilly’s GLP-1 weight-loss pill, was reported to have shown substantial improvement in sleep apnea, adding to the potential uses of the company’s obesity pipeline. Article: Foundayo and sleep apnea
- Positive Sentiment: A recent report says Lilly raised its 2026 sales outlook to as much as $92 billion, reinforcing expectations that strong demand for its obesity and diabetes medicines can drive continued growth. Article: Lilly’s 2026 sales outlook
- Negative Sentiment: Possible new U.S. drug-price negotiations could put pressure on Lilly revenue, according to a report identifying the company as facing nearer-term pricing exposure. Article: Drug-pricing risks
Insider Transactions at Eli Lilly and Company
In other news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.
Eli Lilly and Company Stock Performance
Eli Lilly and Company stock opened at $1,437.46 on Thursday. The firm has a market capitalization of $1.35 trillion, a P/E ratio of 46.66, a PEG ratio of 1.72 and a beta of 0.40. The stock has a fifty day moving average price of $1,231.13 and a 200 day moving average price of $1,106.42. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,453.00. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same period in the prior year, the business posted $7.02 earnings per share. The firm’s revenue for the quarter was up 38.6% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 35.67 earnings per share for the current year.
Eli Lilly and Company Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is currently 22.46%.
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
